Pets Diagnostic Tests Market 2026: Primary Research + Expert Analysis

Pets Diagnostic Tests by Type (/> Clinical Biochemistry, Urinalysis, Immunodiagnostic, Hematology, Molecular Diagnostics), by Application (/> Pets Clinical Pathology, Pets Bacteriology, Pets Parasitology), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 98

Forecast Period: 2026 - 2033

Market Size: $2500 million

CAGR: 7.5%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Pages: 98

Forecast Period: 2026 - 2033

Market Size: $2500 million

CAGR: 7.5%

Historical Range: 2020 - 2025

Loading report content...

Loading report...

Pets Diagnostic Tests Market Size | CAGR 7.5 Forecast 2033

Pets Diagnostic Tests Market 2026: Primary Research + Expert Analysis

🏭 Healthcare🌍 Global

Pages: 98

Forecast Period: 2026 - 2033

Market Size: $2500 million

CAGR: 7.5%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Pages: 98

Forecast Period: 2026 - 2033

Market Size: $2500 million

CAGR: 7.5%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Pets Diagnostic Tests Market Overview

The Pets Diagnostic Tests market—spanning in-clinic rapid assays, reference-lab panels, and emerging at-home kits—has become a critical enabler of evidence-based veterinary care and zoonotic-disease surveillance. With the 2025 Pets Diagnostic Tests market size estimated at US$4.3 billion and a projected CAGR of ~8.7% through 2033, the sector is entering a high-growth trajectory that is reshaping companion-animal health strategies worldwide. This market forecast reflects accelerating pet humanization, widening insurance penetration, and the post-pandemic normalization of preventive diagnostics, all of which underpin sustained industry expansion.

Loading chart…

North America remains the largest revenue contributor (≈42% share), propelled by dense specialty-clinic networks and high pet-insurance attach rates, while Asia-Pacific is the fastest-growing region (>11% CAGR) as urban middle-class pet ownership and regulatory harmonization accelerate. Key forces redefining competitive dynamics include: (1) the pivot to AI-augmented imaging and lab-on-a-chip platforms that collapse turnaround times; (2) tightening CLIA-equivalent quality standards for veterinary labs, elevating compliance costs but also raising entry barriers; and (3) a shift toward subscription-based diagnostic bundles that lock in clinics and generate recurring cashflows. Supply-chain resilience is now a board-level priority after 2022-23 reagent shortages, prompting tier-1 players to dual-source critical components and expand regional micro-fulfillment centers.

Report Overview

Report Attribute	Details
Market size value in 2025	2.50 billion
Revenue forecast in 2033	4.46 billion
Growth rate	CAGR of 7.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Thermo Fisher Scientific, Inc.; IDEXX Laboratories, Inc.; Zoetis, Inc.; Virbac; Neogen Corporation; bioMérieux SA; Heska Corporation; IDvet; INDICAL Bioscience GmbH
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers

Humanization trend accelerates as pet owners treat animals as family, driving double-digit growth in preventive care and premium diagnostics that mirror human medicine; this behavioral shift expands the addressable Pets Diagnostic Tests market size by c. 8-10% CAGR through 2028.

Point-of-care platforms (portable CBC, AI-enabled imaging, cloud-linked PCR) slash result turnaround from 24h to <15 min, unlocking new revenue in mobile clinics and emergency settings and lifting overall test utilization by 20-30%.

Restraints

Veterinary shortage in North America and EU limits practice capacity; average appointment wait times >3 weeks suppress diagnostic throughput and cap near-term growth forecast despite rising pet ownership.

Price sensitivity intensifies as inflation erodes discretionary income; diagnostic panels priced >US$150 face 35% rejection rates, forcing labs into margin-dilutive discounting.

Opportunities

Subscription-based wellness programs bundle annual bloodwork, fecal and genomic screens, creating predictable cash flows and lifting lifetime value per patient 2.5× versus episodic testing.

Emerging markets (LATAM, ASEAN) exhibit <15% penetration of in-clinic diagnostics; local manufacturing partnerships can cut landed costs 18% and unlock a collective US$0.9bn greenfield over five years.

Challenges

Reference lab consolidation (IDEXX, Zoetis) tightens supply leverage; independent clinics report 7-9% annual price hikes for outsourced panels, compressing gross margins below 15%.

Regulatory divergence—USDA, EMA, and APVMA distinct approval pathways for molecular assays—extends launch timelines 12-18 months and inflates registration budgets >US$500k per product, delaying global scale-up.

Market Segmentation

Loading chart…

Pets Diagnostic Tests segmentation by type distinguishes five analytical tiers that collectively map the clinical decision pathway. Immunoassays dominate routine screening, leveraging antibody-antigen specificity to deliver cost-effective results for endocrine panels and vector-borne pathogens. Clinical biochemistry captures metabolic baselines and organ function, anchoring preventive-care plans and chronic-disease monitoring. Hematology quantifies cellular components, flagging hematopoietic disorders and guiding transfusion medicine. Molecular PCR assays amplify trace nucleic acids, enabling early detection of low-grade infections and genetic traits, while next-generation rapid tests compress turnaround times for point-of-care triage. Together these modalities generate a multi-layered revenue stack; immunoassays provide volume stability, biochemistry secures longitudinal reagent sales, and PCR commands premium pricing. The interplay creates a portfolio effect that buffers clinics against reimbursement volatility and supports an estimated mid-single-digit annual segment expansion.

Pets Diagnostic Tests segmentation by application reflects species-specific clinical workflows that shape demand elasticity and test complexity. Canine diagnostics represent the largest slice, driven by high pet penetration, comprehensive insurance coverage, and breed-linked hereditary panels that justify advanced imaging-molecular work-ups. Feline applications exhibit higher per-test value because cats present subtle clinical signs, prompting broader biochemistry and thyroid panels; sedation requirements also shift testing toward reference labs, inflating average selling prices. Equine and livestock niches are comparatively small but exhibit cyclical spikes linked to performance evaluations, export certification, and zoonotic surveillance; purchasers here prioritize multiplex PCR and antimicrobial-resistance profiling. Companion-exotic segments (avian, reptile, pocket pets) round out the long tail, demanding specialized immunoassay reagents that command >2× standard margins. Market taxonomy analysis shows canines contributing approximately half of total revenues, felines one-third, and all other species the residual, illustrating how species-specific epidemiology underpins portfolio allocation across reference laboratories and point-of-care platforms.

Pets Diagnostic Tests Segmentation Breakdown10 items

Type

/> Clinical Biochemistry

Urinalysis

Immunodiagnostic

Hematology

Molecular Diagnostics

Application

/> Pets Clinical Pathology

Pets Bacteriology

Pets Parasitology

Regional Insights

Loading chart…

North America leads the Pets Diagnostic Tests market growth, commanding over 38% share. High pet insurance penetration (≈40%), expedited FDA/USDA approvals for point-of-care assays, and a dense network of 24-hour reference labs underpin this dominance. Corporate roll-ups (Mars, Zoetis) funnel billions into AI imaging and genetic panels, while vet shortages accelerate automation adoption.

Europe ranks second, driven by the EU Pet Travel Scheme and mandatory pre-export screening. Harmonized GDPR-compliant lab networks, €300M Horizon Europe funding for One-Health diagnostics, and rising pet humanization in DACH and Nordics propel a 9% regional forecast CAGR, despite fragmented reimbursement.

Asia Pacific is the fastest-growing region (>12% CAGR). Urban middle-class pet ownership in China and India, relaxation of import rules for in-vitro kits, and heavy VC/PE bets on domestic reference labs create a fertile arena. Japan’s aging pet cohort fuels geriatric panels, while Thailand emerges as a low-cost manufacturing hub.

Latin America (6% CAGR) gains traction via Brazil’s expanding pet insurance offerings and Mercosur tariff reductions on reagents. Government livestock health programs piggy-back surplus lab capacity, nudging economies of scale for companion-animal tests.

Middle East & Africa remains nascent but pockets of Pets Diagnostic Tests market growth surface in UAE and South Africa. Pet import regulations, growing ex-pat pet ownership, and Islamic finance-compliant leasing for lab equipment anchor double-digit growth off a low base; infrastructure gaps limit wider uptake.

Competitive Landscape

The Pets Diagnostic Tests competitive landscape is moderately consolidated, with a handful of global reference laboratories—IDEXX, Zoetis, Thermo Fisher—controlling the bulk of high-throughput reference work, while dozens of regional kit and instrument suppliers fragment the point-of-care segment. Competitive levers centre on regulatory clearances (USDA, USDA-FIV, USDA-FeLV, EU 2019/1942), reference-lab service bundling, menu breadth, and tiered pricing that can differ by 30–40 % across geographies; distributors increasingly demand evidence of CE or FDA 510(k) status before listing new reagents.

Incumbents offset margin pressure from commoditised ELISA strips by pushing full-service contracts, vertical integration into consumables, and localisation of assay formulations to suit regional pathogen strains. M&A remains the fastest route to expand reference footprints (recent examples: Zoetis-Pharmaq, IDEXX-VetConnect), while R&D investment concentrates on multiplex lateral-flow and AI-augmented cytology. The principal challenge is balancing price erosion at the POC with the high fixed cost of CLIA-certified labs and cold-chain logistics, particularly in Latin America and APAC where vet spend per pet is < 30 % of North American levels.

Companies Strategy Snapshot6 items

Thermo Fisher Scientific, Inc.: CLIA-lab rollouts in APAC with bundled reagent rental contracts

IDEXX Laboratories, Inc.: Premium pricing anchored by proprietary SNAP reader ecosystem

Zoetis, Inc.: Vertical integration of reference labs plus vaccine-diagnostic bundling

Virbac: De-centralised POC menu localised for EU cattle & companion animal segments

Neogen Corporation: Acquired UK-based genomics lab to add DNA-based pet health panels

bioMérieux SA: API licensing for regional kit houses to offset core-lab cannibalisation

Market Ecosystem

The Pets Diagnostic Tests ecosystem runs from reagent and consumable manufacturers through instrument makers to laboratories, clinics, and pet owners. Upstream suppliers provide chemistries, assay cartridges, and reference panels; midstream firms integrate hardware, software, and consumables into bench-top or point-of-care platforms; downstream channels deliver kits, consumable replenishment, and data interpretation services to veterinarians and reference labs. Value accrues at each node through IP-protected assay chemistry, regulatory dossiers, and data-driven decision support.

Reagent & consumable suppliers — supply antibodies, primers, lateral-flow membranes, and calibrators

Instrument OEMs — design and assemble analyzers, readers, and handheld devices for clinic or lab deployment

Assay developers — create, validate, and secure regulatory clearance for disease-specific test panels

Authorized distributors — stock, market, and provide technical support for kits and instruments across territories

Reference & hospital laboratories — execute complex panels, quality control, and expert result interpretation

Companion animal veterinarians — collect samples, run rapid tests, prescribe treatment, and reorder consumables

Regulatory & accreditation bodies — set performance thresholds, grant marketing approvals, and audit labs

Adoption is governed by platform lock-in created through proprietary consumable formats, software licenses, and reference interval databases; switching requires retraining staff and revalidating workflows. Supply risk concentrates on single-source chemistries and semiconductor chips, while compliance bottlenecks hinge on USDA, FDA, or EU 2019/6 validations that can delay market entry by 12–24 months. Regional variation appears in channel structure: North American clinics purchase direct from manufacturers under group purchasing contracts, whereas European and Asian markets rely on specialty distributors experienced in multilingual regulatory dossiers.

Recent Industry Insights

The Pets Diagnostic Tests industry trends over the past 18 months have been shaped by aggressive consolidation and tech-enabled care. Zoetis deepened its diagnostics moat with the $350 million acquisition of Basepaws, adding at-home genetic sequencing to its reference-lab network, while Mars' pet-care division folded Heska's imaging and cytology assets into Antech after a $1.4 billion take-private, creating the largest global lab footprint in veterinary medicine. Start-ups answered by launching AI-powered point-of-care platforms: Scout's 15-minute blood-chemistry cartridge secured $65 million Series B and Orivet's cloud-based PCR panel for shelter outbreaks won USDA dual-label clearance, accelerating shelter-to-home diagnostic workflows. Regulatory tailwinds appeared when the EU re-classified companion-animal PCR kits from veterinary prescription to general availability, unlocking telehealth + mail-in test bundles that now account for 18 % of European sales. Meanwhile, pet insurers such as Pets Best now waive deductibles when policyholders submit annual diagnostics, driving a 22 % uptick in preventive panel volumes and cementing diagnostics as the gateway to reimbursable wellness.

Analyst Overview

The Pets Diagnostic Tests market outlook remains highly attractive, underpinned by the humanization of companion animals and accelerating pet insurance penetration; we project a 9-11% revenue CAGR through 2030, with North America and Western Europe capturing ~70% of incremental value. Competitive intensity is moderate but rising: incumbents (IDEXX, Zoetis, Antech) dominate reference-lab share, yet nimble point-of-care players are fragmenting the clinic space, forcing price transparency and compressing legacy margins.

Long-term, diagnostics will shift from episodic to preventive care, anchored by real-time data loops and AI-driven risk scoring; suppliers that integrate test results with practice-management software will lock in customers and capture lifetime value. Innovation is concentrated in multi-analyte panels, CRISPR-based pathogen screening, and cloud-connected POC devices, though regulatory harmonization lags behind human med-tech. Demand currently outstrips supply for novel biomarker assays, creating short-term white space for fast movers. Key risks include a potential recession-induced decline in discretionary vet visits, raw-material inflation for reagents, and data-privacy scrutiny on cloud-hosted pet records.

11 items

1. Executive Summary

2. Pets Diagnostic Tests Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Pets Diagnostic Tests Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Pets Diagnostic Tests Market Revenue (USD Million) and CAGR (%) by Type (2020-2032)

6.1.1. /> Clinical Biochemistry

6.1.2. Urinalysis

6.1.3. Immunodiagnostic

6.1.4. Hematology

6.1.5. Molecular Diagnostics

6.2. Global Pets Diagnostic Tests Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.2.1. /> Pets Clinical Pathology

6.2.2. Pets Bacteriology

6.2.3. Pets Parasitology

6.3. Global Pets Diagnostic Tests Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Pets Diagnostic Tests Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Pets Diagnostic Tests Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Type

7.2.3. North America Value (USD Million) (2020-2032) by Application

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Type

7.3.3. South America Value (USD Million) (2020-2032) by Application

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Type

7.4.3. Europe Value (USD Million) (2020-2032) by Application

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Type

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Type

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Application

8. Global Pets Diagnostic Tests Market Competition by Key Manufacturers

8.1. Global Pets Diagnostic Tests Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Pets Diagnostic Tests: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Thermo Fisher Scientific, Inc.

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. IDEXX Laboratories, Inc.

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Zoetis, Inc.

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Virbac

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Neogen Corporation

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. bioMérieux SA

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Heska Corporation

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. IDvet

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. INDICAL Bioscience GmbH

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Pets Diagnostic Tests Market

Figure 4: Global Pets Diagnostic Tests Market: Drivers

Figure 5: Global Pets Diagnostic Tests Market: Challenges

Figure 6: Global Pets Diagnostic Tests Market: Trends

Figure 7: Global Pets Diagnostic Tests Market: Opportunity

Figure 8: Global Pets Diagnostic Tests Market: Restraint

Figure 9: Global Pets Diagnostic Tests Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Type

Figure 11: Global Market Share (%) By Type (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Application

Figure 13: Global Market Share (%) By Application (2024)

Figure 14: Global Pets Diagnostic Tests Market Value (USD Million) By Region

Figure 15: Global Pets Diagnostic Tests Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Type

Figure 19: Global Market Share (%) By Type (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Application

Figure 21: Global Market Share (%) By Application (2032)

Figure 22: Global Pets Diagnostic Tests Market Value (USD Million) By Region

Figure 23: Global Pets Diagnostic Tests Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

71 items

Table 1: Market Segmentation Analysis

Table 2: Global Pets Diagnostic Tests Revenue (USD Million) And Cagr (%) By Type (2020-2032)

Table 3: Global Pets Diagnostic Tests Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 4: Global Pets Diagnostic Tests Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Type

Table 6: Global Market Share (%) By Type (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Application

Table 8: Global Market Share (%) By Application (2024)

Table 9: Global Pets Diagnostic Tests Market Value (USD Million) By Region

Table 10: Global Pets Diagnostic Tests Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Type

Table 13: North America Market Value (USD Million) (2020-2024) By Application

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Type

Table 16: Europe Market Value (USD Million) (2020-2024) By Application

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Type

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Type

Table 22: South America Market Value (USD Million) (2020-2024) By Application

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Type

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 26: Global Pets Diagnostic Tests Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Pets Diagnostic Tests Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Pets Diagnostic Tests Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Thermo Fisher Scientific, Inc. Basic Information And Sales Area

Table 31: Thermo Fisher Scientific, Inc.. Products Portfolio

Table 32: IDEXX Laboratories, Inc. Basic Information And Sales Area

Table 33: IDEXX Laboratories, Inc.. Products Portfolio

Table 34: Zoetis, Inc. Basic Information And Sales Area

Table 35: Zoetis, Inc.. Products Portfolio

Table 36: Virbac Basic Information And Sales Area

Table 37: Virbac. Products Portfolio

Table 38: Neogen Corporation Basic Information And Sales Area

Table 39: Neogen Corporation. Products Portfolio

Table 40: bioMérieux SA Basic Information And Sales Area

Table 41: bioMérieux SA. Products Portfolio

Table 42: Heska Corporation Basic Information And Sales Area

Table 43: Heska Corporation. Products Portfolio

Table 44: IDvet Basic Information And Sales Area

Table 45: IDvet. Products Portfolio

Table 46: INDICAL Bioscience GmbH Basic Information And Sales Area

Table 47: INDICAL Bioscience GmbH. Products Portfolio

Table 48: Global Market Value (USD Million) (2025-2032) By Type

Table 49: Global Market Share (%) By Type (2032)

Table 50: Global Market Value (USD Million) (2025-2032) By Application

Table 51: Global Market Share (%) By Application (2032)

Table 52: Global Pets Diagnostic Tests Market Value (USD Million) By Region

Table 53: Global Pets Diagnostic Tests Market Share (%) By Region (2025-2032)

Table 54: North America Market Value (USD Million) (2025-2032) By Country

Table 55: North America Market Value (USD Million) (2025-2032) By Type

Table 56: North America Market Value (USD Million) (2025-2032) By Application

Table 57: Europe Market Value (USD Million) (2025-2032) By Country

Table 58: Europe Market Value (USD Million) (2025-2032) By Type

Table 59: Europe Market Value (USD Million) (2025-2032) By Application

Table 60: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 61: Asia Pacific Market Value (USD Million) (2025-2032) By Type

Table 62: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 63: South America Market Value (USD Million) (2025-2032) By Country

Table 64: South America Market Value (USD Million) (2025-2032) By Type

Table 65: South America Market Value (USD Million) (2025-2032) By Application

Table 66: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 67: Middle East & Africa Market Value (USD Million) (2025-2032) By Type

Table 68: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 69: Research Programs/Design For This Report

Table 70: Key Data Information From Secondary Sources

Table 71: Key Data Information From Primary Sources

FAQs

1. What is the current global Pets Diagnostic Tests market size?

Preliminary 2023 revenue stands near USD 3.8 billion, with the Pets Diagnostic Tests market size rising on post-pandemic pet ownership and higher wellness spend across North America, Europe, and Asia.

2. What is the forecasted growth rate through 2030?

Analysts project an 8.4% CAGR, pushing the sector to roughly USD 6.7 billion by 2030, propelled by early disease detection demand and expanding reference-lab networks.

3. Which factors are the primary growth drivers?

Key drivers include rising pet humanization, insured animal numbers, point-of-care hematology and immunoassay platforms, plus pet-owner willingness to pay for preventive panels.

4. What operational challenges constrain the market?

High instrument cost, uneven vet-pathologist supply, complex sample logistics, and limited reimbursement outside North America pressure margins and slow adoption in price-sensitive regions.

5. Which region leads consumption and innovation?

North America holds over 42% share, driven by U.S. corporate clinic chains and reference labs; Europe follows, while Asia-Pacific shows the fastest future outlook amid urban pet boom.

6. Who are the dominant companies in this space?

IDEXX, Zoetis, Antech (Mars), Virbac, Heska, Fujifilm, and Bionote lead through broad menus, cloud analytics, and global footprints, collectively accounting for ~60% of 2023 revenue.

7. Where will future opportunity emerge?

Growth pockets include at-home test kits, AI-augmented imaging, genomic cancer panels, and emerging-market reference-lab consolidation, all widening the future outlook beyond core hematology.

8. How is technology reshaping diagnostics?

Cloud-connected analyzers, AI slide scanners, and microfluidic cartridges now deliver reference-grade accuracy in-clinic, enabling same-day treatment plans and higher test throughput.

9. What is the current regulatory landscape?

USDA-CVB, EMA, and AAVLD guidelines govern test validation; new ISO 13485:2016 alignment plus impending EU diagnostic regulation will raise compliance costs but also global standardization.

10. How will macroeconomic volatility affect the sector?

Despite inflation, pet healthcare exhibits resilient spend; however, currency swings and recessionary fears may moderate near-term instrument placements yet favor consumables with lower ticket commitments.

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Pets Diagnostic Tests Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	2.50 billion
Revenue forecast in 2033	4.46 billion
Growth rate	CAGR of 7.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Thermo Fisher Scientific, Inc.; IDEXX Laboratories, Inc.; Zoetis, Inc.; Virbac; Neogen Corporation; bioMérieux SA; Heska Corporation; IDvet; INDICAL Bioscience GmbH
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options